More than 10 years after its discovery, the function of cyclooxygenase-2 (COX-2) in the cardiovascular system remains largely an enigma. Many scholars have assumed that the allegedly detrimental effects of COX-2 in other systems (e.g. proinflammatory actions and tumorigenesis) signify a detrimental role of this protein in cardiovascular homeostasis as well. This view, however, is ill-founded. Recent studies have demonstrated that ischemic preconditioning (PC) upregulates the expression and activity of COX-2 in the heart, and that this increase in COX-2 activity mediates the protective effects of the late phase of PC against both myocardial stunning and myocardial infarction. An obligatory role of COX-2 has been observed in the setting of late PC induced not only by ischemia but also by d-opioid agonists and physical exercise, supporting the view that the recruitment of this protein is a central mechanism whereby the heart protects itself from ischemia. The beneficial actions of COX-2 appear to be mediated by the synthesis of PGE and / or PGI . Since inhibition of 2 2 iNOS in preconditioned myocardium blocks COX-2 activity whereas inhibition of COX-2 does not affect iNOS activity, COX-2 appears to be downstream of iNOS in the protective pathway of late PC. The results of these studies challenge the widely accepted paradigm that views COX-2 activity as detrimental. The discovery that COX-2 plays an indispensable role in the anti-stunning and anti-infarct effects of late PC demonstrates that the recruitment of this protein is a fundamental mechanism whereby the heart adapts to stress, thereby revealing a novel, hitherto unappreciated cardioprotective function of COX-2. From a practical standpoint, the recognition that COX-2 is an obligatory co-mediator (together with iNOS) of the protection afforded by late PC has implications for the clinical use of COX-2 selective inhibitors as well as nonselective COX inhibitors. For example, the possibility that inhibition of COX-2 activity may augment myocardial cell death by obliterating the innate defensive response of the heart against ischemia / reperfusion injury needs to be considered and is the object of much current debate. Furthermore, the concept that the COX-2 byproducts, PGE and / or PGI , play a necessary role in late PC 2 2 provides a basis for novel therapeutic strategies designed to enhance the biosynthesis of these cytoprotective prostanoids in the ischemic myocardium. From a conceptual standpoint, the COX-2 hypothesis of late PC expands our understanding of the function of this enzyme in the cardiovascular system and impels a critical reassessment of current thinking regarding the biologic significance of COX-2. 
against both reversible (stunning) and irreversible (infarc-2 . Mechanism of late PC tion) myocardial ischemia / reperfusion injury [2] . During the past decade, late PC has become the focus of intense
The shift of the heart to a late preconditioned (defensive) investigative efforts aimed at identifying the molecular phenotype is the result of a complex cascade of molecular mechanisms that underlie this powerful defensive adaptaevents that begins with an effective PC stimulus (such as tion of the heart. The clinical implications of these studies reversible ischemia or pharmacologic and physical stimuli) are potentially vast, since elucidation of the molecules that and culminates in the synthesis of new proteins that render confer the preconditioned phenotype could conceivably the heart tolerant to subsequent ischemic injury [2] (Fig. enable therapeutic exploitation of this endogenous protec-1). The elements that constitute this molecular cascade can tive mechanism in patients with coronary artery disease be conceptually subdivided into three major components: who are at risk of acute myocardial infarction or other (i) 'triggers' or initiators of late PC, (ii) 'mediators' or acute coronary events.
effectors of late PC, and (iii) signaling pathways that Fig. 1 . Schematic representation of our current understanding of the cellular mechanisms whereby COX-2 is upregulated by ischemic PC and participates in cardioprotection. A sublethal ischemic stress (ischemic PC) activates a complex signal transduction cascade that includes PKC (specifically, the e isoform), PTKs (specifically, Src and / or Lck kinases), and probably other as-yet-unknown kinases, leading to phosphorylation of IkBa and mobilization of the transcription factor NF-kB. In addition, ischemic PC activates the non-receptor tyrosine kinases JAK1 and JAK2 with subsequent tyrosine phosphorylation and activation of the transcription factors STAT1 and STAT3. Other, as yet unknown, transcription factors are most likely involved as well. The promoter of both the iNOS and the COX-2 genes contains cognate sequences for NF-kB and STAT1 / STAT3. Binding of NF-kB and STAT1 / STAT3 to these promoters results in a coordinated transcriptional activation of the iNOS and COX-2 genes with synthesis of new iNOS and COX-2 proteins. The activity of newly-synthetized COX-2 protein requires iNOS-dependent NO generation whereas the activity of iNOS does not require COX-2-dependent prostanoid generation. Thus, COX-2 is downstream of iNOS in the pathophysiological cascade of late PC. iNOS-derived NO can protect the myocardium from recurrent ischemia both via direct actions and via activation of COX-2-dependent synthesis of cardioprotective prostanoids. Among the products of COX-2, PGE and / or PGI appear to be the most likely effectors of cytoprotection. A similar upregulation of COX-2 can be elicited 2 2 pharmacologically by d-opioid receptor agonists but not by adenosine A or A receptor agonists. 1 3 connect these two groups of molecules [2] (Fig. 1) . Several that COX-2 activity is essential for late PC to occur, chemical species, including nitric oxide (NO), reactive supporting a cytoprotective role of this protein and chaloxygen species, adenosine, and opioids, have been shown lenging the common paradigm that COX-2 activity is to serve as triggers of the late PC response [2] . These detrimental. The purpose of the present essay is to review triggers activate a series of kinases and transcription the evidence supporting the recent recognition that COX-2 factors that include the e isoform of PKC, the Src and / or is a cardioprotective enzyme. We will first review the role Lck isoform of the Src family of protein tyrosine kinases of COX-2 in the late phase of ischemic and pharmacologic (PTKs), Janus kinases (JAK) 1 and 2, nuclear factor-kB PC and then its role in the early phase of ischemic PC and (NF-kB), signal transducers and activators of transcription in nonpreconditioned myocardium. (STAT) 1 and 3, and probably other as-yet-unknown kinases and transcription factors [2] (Fig. 1) . Recruitment of these pathways eventually culminates in transcriptional 4 . Role of COX-2 in ischemia-induced late PC activation of cardioprotective genes and increased expression of proteins that confer resistance to ischemic injury 4 .1. Ischemic PC upregulates COX-2 (mediators of late PC). The first mediator of late PC to be identified was the inducible isoform of nitric oxide synthFor this and other studies, we utilized a well-established ase (iNOS) [3] [4] [5] [6] . However, given the complexity of the conscious rabbit model of late PC [3, 4, [46] [47] [48] . The first signaling pathways activated during late PC, it seemed question we addressed was: Is COX-2 induced by the brief implausible to us that iNOS would be the only cardioepisodes of ischemia that elicit late PC? Rabbits were protective protein involved. We postulated that late PC is a preconditioned with a sequence of six 4-min coronary polygenic response that requires the coordinated upregulaocclusion / 4-min reperfusion cycles (a protocol that has tion of multiple proteins.
been shown to induce late PC against both myocardial stunning and myocardial infarction [3, 4, [46] [47] [48] ) and were euthanized at selected times thereafter. RNase protection 3 . Rationale for the COX-2 hypothesis of late PC assays were used to detect and quantitate COX-2 mRNA in myocardial tissue samples [46] . Low but detectable COX-2 Cyclooxygenase (COX)-2 is the rate-limiting enzyme in mRNA levels were present in control rabbits. COX-2 prostaglandin (PG) synthesis, catalyzing the conversion of mRNA levels were significantly increased in the ischemicarachidonic acid to PGH [7, 8] . Two distinct COX isoreperfused region at 1 h after ischemic PC (1231664%), 2 forms have been characterized so far: COX-1, which is remained elevated at 3 h, and returned to near control present in most cells and is responsible for constitutive values by 24 h (Fig. 2) . We then analyzed COX-2 protein prostanoid formation, and COX-2, which is induced in expression in samples harvested 24 h after ischemic PC response to stress but is also constitutively expressed in using standard Western immunoblotting. In control rabbits, some tissues (e.g. kidney, brain, endothelial cells) [7, 8] .
over 99% of total COX-2 protein was found in the Our hypothesis that COX-2 is a co-mediator of the membranous fraction. Fig. 3 illustrates a representative protection afforded by late PC (together with iNOS) was Western immunoblotting analysis of COX-2. A weak predicated on several considerations. First, COX-2 is COX-2 signal was detected in control hearts. When rabbits known to be co-induced together with iNOS in various cell were preconditioned 24 h earlier, the expression of COX-2 types, including cardiac myocytes, in response to stresses in the ischemic-reperfused region increased significantly such as cytokines, hypoxia, and ischemia [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . Second, (1216679%) [10] . No COX-2 immunoreactivity was the signaling elements that control the expression of COXdetectable in the cytosolic fractions of preconditioned 2 during stress appear to be similar to those that control the hearts [46] . induction of iNOS, because they include reactive oxygen To determine whether the increased COX-2 protein species [9, 22] , protein kinase C (PKC) [23, 24] , protein expression was associated with increased COX-2 entyrosine kinases (PTKs) [25, 26] , and nuclear factor-kappa zymatic activity, the myocardial content of the major B (NF-kB) [10, 22, 27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] . Despite these facts, however, virtually and 6-keto-PGF (1250685 and 12596107%, respec1a nothing was known regarding the role of COX-2 either in tively, vs. controls) in the ischemic-reperfused region 24 h ischemic PC or in myocardial ischemia / reperfusion in later (Fig. 4) [46] . PGF levels were also elevated but to a 2a general. much lesser extent (Fig. 4) PC. As indicated above, the doses of NS-398 and celecoxib used in our study [46] effectively ablated the increased (Fig. 4) [46] . Thus, the doses of NS-398 and celecoxib COX-2 activity associated with late PC (Fig. 4) , thereby used in this study were effective in blocking the increase in providing a pharmacologic tool to interrogate the func-COX activity associated with ischemic PC. Importantly, tional significance of COX-2 in this phenomenon. Accordneither NS-398 nor celecoxib lowered prostanoid levels in ingly, we carried out studies to determine whether these the nonischemic region below control values (Fig. 4) , same doses of NS-398 and celecoxib interfere with the indicating that constitutive COX activity (COX-1) was not cardioprotective effects of late PC. Because myocardial suppressed by these drugs. There was no significant stunning and myocardial infarction are two different difference in the myocardial content of PGD or TXB phenomena [49], we studied late PC against stunning and 2 2 between control and preconditioned hearts [46] . Taken late PC against infarction separately. together, these results (Figs. 2-4) demonstrate that isTo examine late PC against stunning, conscious rabbits chemic PC upregulates the myocardial expression and were subjected to a sequence of six 4-min coronary activity of COX-2.
occlusions / 4-min reperfusion cycles for three consecutive days (days 1, 2, and 3) [46] . The recovery of regional 4 .2. COX-2 activity is necessary for the protective myocardial function was assessed as left ventricular (LV) effects of ischemia-induced late PC against myocardial systolic thickening fraction by using the pulsed Doppler stunning probe [47] . The total deficit of systolic wall thickening (WTh) after reperfusion (an integrative assessment of the The next logical question was: Does the upregulation of overall severity of myocardial stunning) [47] was calcu-COX-2 following ischemic PC play a necessary role in the lated by measuring the area comprised between the systolic manifestation of the preconditioned phenotype (i.e. of WTh-vs.-time line and the baseline (100% line) during the h earlier, the levels of PGE and 6-keto-PGF in the ischemic-reperfused region increased markedly vs. control rabbits; the levels of PGF were higher 2 1 a 2a than in the nonischemic region of the same group but did not differ significantly from controls. The increase in PGE , PGF , and 6-keto-PGF was 2 2 a 1a completely abrogated when rabbits were given NS-398 or celecoxib 24 h after ischemic PC (40 min before euthanasia). The myocardial content of PGE 2 and 6-keto-PGF in the nonischemic region was similar in all groups, indicating that the COX-2 inhibitors did not affect constitutive production of these 5-h recovery phase after the sixth reperfusion. In all day 1 (Fig. 5 ). This indicates the development of late PC groups, thickening fraction on day 1 remained significantly against stunning [3, [46] [47] [48] . Similar results were obtained depressed for 4 h after the sixth reperfusion and returned to in rabbits given DMSO (the vehicle used for both NS-398 values not significantly different from preocclusion values and celecoxib) on day 2 ( Fig. 5 ). When rabbits were given by 5 h. Thus, as previously observed in this model [3,46- NS-398 or celecoxib prior to the six occlusion / reperfusion 48], the sequence of six 4-min coronary occlusion / 4-min cycles on day 2, however, the recovery of WTh during the reperfusion cycles resulted in severe stunning that lasted, 5-h reperfusion period was not improved on day 2 comon average, for 4 h. As expected [3, [46] [47] [48] , in control pared with day 1, so that the total deficit of WTh did not rabbits the recovery of WTh was improved on days 2 and differ significantly between day 1 and day 2 (Fig. 5) . Thus, 3 compared with day 1, resulting in a significant decrease the protective effects of late PC against stunning on day 2 in the total deficit of WTh on both days, compared with were completely abrogated by the administration of either Fig. 5 . Total deficit of WTh after the sixth reperfusion (a measure of the severity of myocardial stunning) on days 1, 2, and 3 in groups VII (control, n510), VIII (DMSO on day 2, n57), IX (NS-398 on day 1, n59), X (NS-398 on day 2, n510), XI (celecoxib on day 1, n59) and XII (celecoxib on day 2, n510). The total deficit of WTh was measured in arbitrary units, as described in the text. Data are means6S.E.M. (Reproduced with permission of the National Academy of Sciences from Shinmura et al. [46] ).
NS-398 or celecoxib. Administration of NS-398 or analogous to that observed in the rabbit (Fig. 7) [52]. As celecoxib on day 1 had no effect on the deficit of WTh on we had found in rabbits, this cardioprotective effect was the same day ( Fig. 5) , indicating that these drugs, in ablated when mice were given NS-398 prior to the 30-min themselves, do not affect the severity of myocardial coronary occlusion, indicating that COX-2 activity is stunning in nonpreconditioned myocardium.
essential for the infarct-sparing effects of late PC in mice (Fig. 7) . infarction In summary, these two studies [46, 52] demonstrate that COX-2 plays an obligatory role in the cardioprotective To examine late PC against infarction, conscious rabbits effects of ischemia-induced late PC in two different were preconditioned with a sequence of six 4-min coronary species (rabbits and mice), supporting the notion that the occlusion / 4-min reperfusion cycles and then subjected, 24 recruitment of this protein is a general mechanism underlyh later, to a 30-min coronary occlusion followed by 3 days ing cardiac adaptation to stress. Furthermore, COX-2 is of reperfusion. As expected [4, 46, 48, 50] , infarct size was essential both for late PC against stunning and for late PC significantly smaller in rabbits subjected to six occlusion / against infarction. reperfusion cycles 24 h earlier (PC group) compared with controls, indicating a late PC effect against myocardial infarction (Fig. 6 ) [46] . In contrast, in rabbits treated with 5 . Role of COX-2 in pharmacologic PC either NS-398 or celecoxib prior to the 30-min occlusion, infarct size was similar to that measured in controls (Fig.
5 .1. COX-2 activity is necessary for the protective 6), indicating that both drugs abrogated late PC. When effects of d-opioid receptor-and NO donor-induced late NS-398 or celecoxib were given in the absence of ischemic PC PC, infarct size did not differ from that observed in controls (Fig. 6 ), indicating that these drugs did not affect
Having identified an obligatory role of COX-2 in the extent of cell death in nonpreconditioned myocardium ischemia-induced late PC, we sought to determine whether [46] . This finding suggests that COX-2 activity does not pharmacologic and other stimuli known to induce a late PC play an important role in modulating infarct size in naıve response also act via upregulation of COX-2 activity. (nonpreconditioned) myocardium.
Activation of d-opioid receptors has been shown to elicit To determine whether the obligatory role of COX-2 in a delayed cardioprotective effect against myocardial infarclate PC is species-specific, we then examined the role of tion that mimics that induced by ischemia [53, 54] . In COX-2 in the mouse utilizing a well-established model of recent studies in conscious rabbits, we have found that myocardial infarction [51] produced by a 30-min coronary administration of the d-opioid receptor agonist BW373U86 occlusion followed by 24 h of reperfusion. As expected alleviates the myocardial stunning induced 24 h later by a [51], ischemic PC (six 4-min coronary occlusion / 4-min sequence of six 4-min occlusion / reperfusion cycles (dreperfusion cycles) resulted, 24 h later, in a significant opioid-induced late PC against stunning). We used this reduction in infarct size, indicating a late PC effect model to test the role of COX-2. When rabbits were given the COX-2 inhibitors NS-398 or celecoxib prior to the cardioprotection [57] . Nevertheless, since COX-2 is consequence of six occlusion / reperfusion cycles 24 h after stitutively expressed in the rabbit heart [46, 50] , it remains BW373U86, the recovery of WTh was indistinguishable possible that this enzyme might be activated 24 h after from control rabbits, indicating that the late PC effect CCPA or IB-MECA treatment and thus contribute to against stunning was ablated. In addition, BW373U86 cardioprotection even though its protein expression is upregulated the myocardial expression of COX-2 protein unchanged. To test this possibility, infarct size was meaand the content of PGE and 6-keto-PGF 24 h later. sured in rabbits subjected to a 30-min coronary occlusion
Taken together, these data demonstrate that activation of followed by 72 h of reperfusion [50] . Both CCPA and d-opioid receptors upregulates COX-2 activity in the IB-MECA, given 24 h prior to the 30-min occlusion, myocardium and that this phenomenon plays an obligatory resulted in a significant reduction in infarct size indicative role in d-opioid receptor-induced late PC against myocarof a late PC effect, consistent with prior observations [57] . dial stunning.
Administration of NS-398 at the same dose that was Furthermore, in recent studies in mice subjected to a previously shown to effectively abolish the enhanced 30-min coronary occlusion followed by 24 h of reperfu-COX-2 activity elicited by ischemia and the concomitant sion, we have found that administration of COX-2 incardioprotection in the same conscious rabbit model [46] , hibitors shortly before the 30-min occlusion blocks the late failed to block the infarct-sparing effects of either CCPA or PC effect induced by pretreatment with NO donors IB-MECA, indicating that COX-2 activity is not necessary (DETA / NO) as well as that induced by prior physical for these effects to occur [50] . Thus, unlike d-opioid exercise, indicating that COX-2 is also a mediator of NO receptor-induced late PC against stunning, the mechanism donor-induced and exercise-induced late PC.
of adenosine A and A receptor-induced late PC against 1 3 infarction is independent of COX-2 activity. 6 The adenosine A receptor agonist 2-chloro-NAlthough COX-2 has been found to be upregulated by 1 cyclopentyladenosine (CCPA) and the adenosine A rephorbol ester and oxidative stress in isolated neonatal 3 6 ceptor agonist N -3-iodobenzyladenosine-59-N-methylcarmyocytes [9], no information is available regarding the boxamide (IB-MECA) have been shown to elicit a delayed modulation of COX-2 in adult myocardium. Specifically, phase of protection against infarction similar to the late nothing is known regarding the signaling pathways wherephase of ischemia-induced PC [55] [56] [57] . Using our conby a sublethal ischemic stress leads to increased expression scious rabbit model, we found that neither CCPA nor of COX-2 in the heart. Since the development of late PC is IB-MECA upregulated COX-2 protein expression 24 h triggered by the formation of NO and reactive oxygen after their administration [50] , despite the fact that both of species during the initial PC stimulus and by the subthese agonists were given in doses that elicit delayed sequent early activation of a cascade that involves the sequential recruitment of PKC, Src / Lck PTKs, and NF-kB relationship between iNOS and COX-2 in the heart has not [2] , it seemed logical to hypothesize that these elements been evaluated. participate in the induction of COX-2 in response to
.2. COX-2 activity is not necessary for adenosine A 1 or A receptor-induced late PC against myocardial
3 infarction
. Mechanism of upregulation of COX-2 by ischemia
In a recent study [58] , we have examined this issue in sublethal myocardial ischemia.
the same conscious rabbit model in which the role of Using our conscious rabbit model, we found [58] that COX-2 was previously demonstrated [46] . We found that the increase in COX-2 protein expression observed 24 h the increase in myocardial prostanoids (PGE and 6-keto-2 after ischemic PC was completely prevented when the PGF ) observed 24 h after ischemic PC (on day 2) was 1a animals were pretreated (before the PC protocol) with the ablated when two selective iNOS inhibitors (SMT and PKC inhibitor chelerythrine, the tyrosine kinase inhibitor 1400W) were given on day 2, 30-40 min prior to lavendustin-A, or the NF-kB inhibitor diethyldithiocarharvesting of tissue samples [58] . On the other hand, bamate (DDTC), given at doses which completely inhibit administration of NS-398 or celecoxib on day 2 did not activation of PKCe [59], Src and Lck PTKs [60], and have any appreciable effect on iNOS activity. These data NF-kB [61] , respectively, in this rabbit model. Thus, indicate that the enhanced prostanoid biosynthesis associinduction of COX-2 protein expression in preconditioned ated with late PC is dependent upon iNOS-derived NO myocardium requires PKC-, Src / Lck PTK-, and NF-kBwhereas the enhanced iNOS activity is independent on dependent signaling (Fig. 1) . In contrast, administration of COX-2-derived prostanoids [58] . Thus, COX-2 is located the antioxidant N-2-mercaptopropionyl glycine (MPG) or downstream of iNOS in the protective pathway of late PC, v the NOS inhibitor N -nitro-L-arginine (L-NA) prior to implying that iNOS protects, at least in part, by recruiting ischemic PC did not block the upregulation of COX-2 24 h COX-2. We propose that stimulation of COX-2 activity later, indicating that the generation of NO and reactive and production of cytoprotective prostanoids, such as oxygen species during the PC ischemia is not necessary for PGE and PGI , may be a previously unrecognized 2 2 the increase in COX-2 protein expression to occur [58] . mechanism by which NO exerts its salubrious effects on Since both L-NA and MPG were given in doses that the ischemic myocardium (Fig. 1) . completely block the development of late PC in this Interestingly, the increase in prostanoid levels 24 h after conscious rabbit model [3, 47, 48, 62] , the failure of these ischemic PC was not affected by the administration on day agents to block COX-2 induction [58] implies that NO and 2 of the soluble guanylyl cyclase inhibitor ODQ (given at reactive oxygen species participate in the late phase of doses that block the increase in cGMP levels associated ischemic PC by upregulating proteins other than COX-2 with late PC [77] ), indicating that iNOS-derived NO (e.g. iNOS) [3] [4] [5] [6] , thereby supporting the notion [2] that activates cardiac COX-2 via cGMP-independent mechathe switch of the heart to a preconditioned phenotype is a nisms [58] . This supports the hypothesis of a direct polygenic response (i.e. COX-2 induction is necessary but interaction between NO and the COX-2 molecule [65]. not sufficient). As the activation of COX-2 gene transcription usually requires the combinatorial actions of various transcription factors [7, 63] , it seems very likely that the 8 . Does aspirin abrogate COX-2-dependent late PC? mechanism responsible for upregulating this enzyme in the heart is much more complex. Further studies will be Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit needed to decipher the intricate network of kinases and COX activity and are widely used clinically. transcription factors that underlie the recruitment of this Acetylsalicylic acid (aspirin) is the most commonly used cardioprotective protein.
NSAID for relieving pain, inflammatory symptoms, and fever [78] . In addition, aspirin has established efficacy for preventing cardiovascular events [78] [79] [80] . Aspirin inhibits COX-1 activity by acetylating serine 530, which is located 7 . COX-2 activity in preconditioned myocardium is close to the active site (tyrosine 385) of COX-1; acetylamodulated by iNOS tion of this serine residue hinders the access of arachidonic acid to the catalytic site [81, 82] . Aspirin also inhibits As indicated above, iNOS plays a necessary role in COX-2 by a similar mechanism but with less potency [83] . mediating the cardioprotective effects of late PC [3] [4] [5] [6] .
Although the ability of low doses of aspirin to inhibit Since both iNOS and COX-2 are obligatory co-mediators COX-1 activity is well established [78, 84] , it is unknown of late PC, the question naturally arises to whether these whether these doses can also interfere with the cardiotwo proteins act in series or are independent (i.e. parallel) protective effects of late PC by inhibiting COX-2 as well. effectors of cardioprotection. A possible 'cross-talk' beMounting evidence indicates that both ischemic and phartween NOS and COX has been extensively examined in macologic PC occur in patients with coronary artery noncardiac tissues, with conflicting results (reviewed in disease [85, 86] . Since aspirin at low doses is currently Ref.
[64]). While some studies suggest that NO enhances recommended for the prophylaxis of cardiac and cerebral COX-2 activity [16, [65] [66] [67] [68] , others have concluded that ischemic events and is given to almost all patients with NO inhibits it [69] [70] [71] [72] [73] or has no effect [74] [75] [76] . The coronary artery disease [78] , it is important to determine whether the use of aspirin affects the development of late injury and apoptosis, indicating that COX-2 is protective in PC.
this system [9] . A pro-apoptotic effect of inhibiting COX-2 We have recently examined this issue in conscious has also been reported in other cell types [93] [94] [95] . In a rabbits in which late PC against stunning was induced with recent study in isolated mouse hearts [92] , Camitta et al. a sequence of six 4-min coronary occlusion / 4-min reperfu- [92] found that the postischemic recovery of LV function sion cycles on three consecutive days [87] . We found that was impaired in COX-2 null mice compared with controls, administration on day 2 of 5 mg / kg of aspirin, which was implying that constitutively-expressed COX-2 is cardiosufficient to inhibit platelet aggregation, did not inhibit protective. Interestingly, COX-2 protein was not detectable either the increase in myocardial levels of PGE and by Western immunoblotting in wild-type hearts; however, 2 6-keto-PGF or the late PC protection against myocardial PGE and 6-keto-PGF were still present in COX-1 null 1a 2 1 a stunning; in contrast, administration on day 2 of 25 mg / kg hearts (albeit at lower levels than in controls), suggesting of aspirin completely abrogated both the increase in that sufficient COX-2 was present under baseline conmyocardial prostanoids and the cardioprotective effects of ditions to generate these prostanoids [92] . This concept is late PC [87] . Thus, low doses of aspirin, which are widely corroborated by the finding that loss of COX-2 aggravated used to prevent cardiovascular events in patients, do not ischemia-reperfusion injury [92] , which implies that coninterfere with the cardioprotective effects of late PC stitutively-expressed COX-2 is sufficient to produce caragainst myocardial stunning. In contrast, higher doses of dioprotective prostanoids even though its protein expresaspirin, which are used for analgesic / antipyretic purposes, sion may not be detectable. The fact that ablation of completely abrogate late PC, suggesting that they should COX-2 exacerbated ischemia-reperfusion injury also imbe used with caution in patients with atherosclerotic plies that COX-1 cannot substitute for the loss of COX-2. cardiovascular disease, since they may deprive the heart of Taken together, the observation of Camitta et al. [92] its innate defensive response. That low-dose aspirin inhibsupport a cardioprotective role of constitutively-expressed its platelet aggregation (a COX-1-dependent phenomenon) COX-2 in the heart, a novel concept that warrants further but not late PC (a COX-2-dependent phenomenon) probainvestigation. Interestingly, acute inhibition of COX-2 with bly results from the fact that aspirin exhibits less potency indomethacin failed to exacerbate ischemia-reperfusion for COX-2 than for COX-1 inhibition [83] because the injury while supplementation with prostaglandins failed to substrate channel of COX-2 is larger and more flexible reverse the detrimental effects of COX-2 deletion, sugthan that of COX-1 [88] . For example, in intact cells gesting that in that study COX-2 protected the heart by aspirin is 166 times more active against COX-1 (IC 50.3 indirect actions [e.g. altered expression of other gene(s)] 50 mg / ml) than against COX-2 (IC 550 mg / ml) [83] . The rather than by the direct effects of its metabolites [92] . 50 results summarized above [87] were obtained in the context of late PC against stunning; whether similar conclusions apply to late PC against infarction is not 1 1. Mechanism of COX-2-mediated cardioprotection known.
COX-2 catalyzes the conversion of arachidonic acid to PGH , which can be metabolized to various eicosanoids, 2
. Role of COX-2 in early PC
including PGD , PGE , PGF , PGI , and TXA [7, 8] .
The precise range of prostanoids generated by COX-2 Studies of the effects of nonselective COX inhibitors on depends on the cell types and their inherent prostanoid early PC have yielded conflicting results [89] [90] [91] . Perhaps synthetic pathways [7, 8] . Our published data in rabbits the most conclusive study is that of Camitta et al. [92] , [46] as well as unpublished data in mice indicate that the who found that deletion of either COX-1 or COX-2 by two main products of COX-2 activity in preconditioned gene targeting had no effect on early PC in isolated mouse myocardium are PGE and PGI (Fig. 3) , suggesting that 2 2 hearts. the cardioprotective effects of COX-2 are related to the biological actions of these two prostanoids. A large number of studies have shown that PGE and PGI (and 1 0. Effect of COX-2 on ischemia / reperfusion injury their analogs) exert salutary actions during myocardial in nonpreconditioned myocardium ischemia / reperfusion, resulting in attenuation of stunning [96, 97] and reduction in infarct size [29] [30] [31] 35 Our finding that COX-2 is an obligatory co-mediator of 41, 44, 45, 98] . The cytoprotective actions of PGE and PGI 2 2 protection during late PC is consistent with an increasing have been attributed to antagonism of adenylyl cyclase number of reports in other systems suggesting a beneficial [28, [34] [35] [36] 42, 99, 100] , activation of ATP-sensitive potas- 21 role of this enzyme in ischemia and other settings. Studies sium channels [36, 40, 41, 99] , inhibition of Ca influx in isolated neonatal cardiomyocytes have shown that [99] , and attenuation of neutrophil infiltration oxidative stress upregulates COX-2 and the addition of a [38, 39, 44, 45] (Table 1) . Interestingly, these actions are COX-2-specific inhibitor enhances oxidative stress-induced reminiscent of those of NO [101] , suggesting that pros- [129] ) has concluded The conclusion that COX-2 mediates the beneficial that these agents significantly increase the risk of myocareffects of late PC may seem surprising or even paradoxidial infarction [123] . One explanation put forth for these cal, because the activity of COX-2 is generally thought to differences was that COX-2 inhibitors may have a protbe detrimental [8, 21] . Specifically, induction of COX-2 is hrombotic action, since they suppress endothelial probelieved to play a role in inflammation, toxic shock, duction of PGI (which is mostly derived from COX-2 2 cancer, and apoptosis [8, 21, 71, [104] [105] [106] [107] [108] [109] [110] [111] . A recent study [115, 121, 122] ) while leaving platelet production of TBA 2 has reported the expression of COX-2 in ischemic human (which is exclusively due to COX-1 [8, 119, 122] ) unmyocardium and in dilated cardiomyopathy, but not in altered, thereby causing an imbalance between antithromnormal cardiomyocytes [112] , a finding which has been botic and prothrombotic prostanoids [122, 123] . Another interpreted (without proof) to indicate a role of COX-2 in possibility, however, is that COX-2 antagonists may cardiac disease. Evidence has been reported suggesting abrogate late PC, thereby increasing the severity of that COX-2 contributes to ischemia / reperfusion injury in myocardial ischemia / reperfusion injury. Regardless of the the brain [113, 114] . mechanism involved, a prospective randomized trial of the However, there is also evidence suggesting physiologieffect of COX-2 inhibitors on cardiovascular events seems cally important or salutary actions of COX-2 in other warranted [123] . situations [9, 93-95, [119, 122, 123] . The finding that genetic disruption ill-founded. Asides from the fact that a causative role of of COX-2 results in cardiac fibrosis [116] also suggests COX-2 activity in many of the aforementioned processes that COX-2 expression may be protective. Furthermore, it has not been proven but rather has been suspected on the is now recognized that COX-2 is constitutively expressed basis of correlative data, tumorigenic and proinflammatory in the kidney [120, 124] and in the brain [125] [126] [127] and actions in other organs cannot be extrapolated to signify plays an important role in maintaining renal function detrimental cardiovascular actions without data. [119, 120] and in modulating neural responses [119] .
The evidence reviewed herein expands our understandWhether COX-2 exerts proinflammatory actions in reing of this protein. Specifically, the discovery that COX-2 perfused myocardium remains unknown; even if it does, activity plays an indispensable role in the antiischemic that inhibition of COX-2 activity may augment myocardial 
